Acetyl-L-carnitine for patients with hepatic encephalopathy

dc.creatorArévalo Rodríguez, Ingrid
dc.creatorMartí Carvajal, AJ
dc.creatorGluud, C
dc.date.accessioned2022-04-07T15:55:56Z
dc.date.accessioned2022-09-27T12:45:19Z
dc.date.available2022-04-07T15:55:56Z
dc.date.available2022-09-27T12:45:19Z
dc.date.created2022-04-07T15:55:56Z
dc.date.issued2014-12
dc.identifier1469-493X
dc.identifierhttps://repositorio.fucsalud.edu.co/handle/001/2688
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3597094
dc.description.abstractThis is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the clinical benefits and harms of acetyl-L-carnitine for treating patients with hepatic encephalopathy
dc.languageeng
dc.publisherJohn Wiley and Sons
dc.publisherEstados Unidos
dc.relationCochrane Database of Systematic Review
dc.relation15
dc.relationArt. No. CD011451
dc.relation1
dc.relation12
dc.relationCochrane Database of Systematic Review
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.sourcehttps://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011451/epdf/full
dc.titleAcetyl-L-carnitine for patients with hepatic encephalopathy
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución